Ovid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. OVID, a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer, will present at the Cowen and Company 40^th Annual Health Care Conference on Monday, March 2, 2020 at 3:30 p.m. EST. The conference will be held at the Boston Marriot Copley Place in Boston, MA.

A live audio webcast of the presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the company's website for two weeks following the live presentation.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine^® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company's most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935/TAK935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).

For more information on Ovid, please visit http://www.ovidrx.com/.

Contacts

Investors and Media:

Ovid Therapeutics Inc.

Investor Relations & Public Relations

irpr@ovidrx.com

Or

Investors:

Steve Klass

Burns McClellan, Inc.

sklass@burnsmc.com

(212) 213-0006

Media:

Katie Engleman

1AB

katie@1abmedia.com

(919) 333-7722